Lung Injury for Pediatric Bone Marrow Transplant
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve the understanding and treatment of lung problems in children undergoing hematopoietic stem cell transplant (HSCT), a procedure for treating blood disorders like sickle cell disease. Researchers seek better methods to diagnose and treat early lung injuries, such as bleeding or infections, and later issues, like severe breathing problems linked to chronic complications. The trial involves collecting health data and biological samples from children receiving HSCT to identify the causes of lung injury and test new treatments. Suitable participants include children or young adults up to 24 years old undergoing this type of stem cell transplant.
As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could significantly advance the treatment of lung complications after stem cell transplants.
Why are researchers excited about this trial?
Researchers are excited about the TRANSPIRE trial because it aims to uncover how lung injuries develop and progress in children who have undergone hematopoietic stem cell transplantation (HSCT). Unlike treatments that directly address lung injury symptoms, this trial focuses on understanding the underlying mechanisms and risk factors over time. By following patients longitudinally, researchers hope to discover potential early indicators of lung injury, which could lead to more effective prevention and treatment strategies in the future. This approach is different from current options because it seeks to prevent lung injury before it becomes severe, rather than just treating it after it occurs.
Who Is on the Research Team?
Stella Davies, MBBS, PhD, MRCP
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo allogeneic hematopoietic stem cell transplantation (alloHSCT) and are monitored for early pulmonary injury
Follow-up
Participants are monitored for lung injury and other complications after HSCT
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor